Premium
Long‐term survival of a child with refractory anaplastic large cell lymphoma following therapy with an antisense oligonucleotide, topotecan, and vinblastine
Author(s) -
Wrobel Grazyna,
Chaber Radosław,
Rygier Jolanta,
Bonar Jolanta,
MuszynskaRoslan Katarzyna,
Chybicka Alicja
Publication year - 2015
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.1006
Subject(s) - vinblastine , topotecan , medicine , chemotherapy , lymphoma , refractory (planetary science) , anaplastic large cell lymphoma , oncology , antisense therapy , transplantation , large cell , cancer research , oligonucleotide , cancer , biology , adenocarcinoma , dna , genetics , locked nucleic acid , astrobiology
Abstract Anaplastic large cell lymphoma includes a subset of highly aggressive tumours and has a relapse rate of 30% at 2 years. Relapsed patients often have poor clinical outcome. The use of antisense oligonucleotides to down‐regulate Bcl‐2 protein can reverse chemotherapy resistance. The authors describe an 11‐year‐old boy with recurrent anaplastic large cell lymphoma who had received double high‐dose chemotherapy followed by autologous haematopoietic stem‐cell transplantation, had refractory disease and then had achieved long‐term remission with the use of an antisense oligonucleotides in combination with vinblastine and topotecan. Copyright © 2011 John Wiley & Sons, Ltd.